EXKIVITY
PeakNDAORALCAPSULEPriority Review
Approved
Sep 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 43m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EXKIVITY is an oral small-molecule capsule approved by the FDA in September 2021 under Takeda's sponsorship. The mechanism of action and specific indications are not publicly disclosed in available data. Patient population and therapeutic use case remain to be determined from clinical or label information.
$10MPart D
Peak8.5 years to LOEThe product is in peak commercial phase with modest Part D claims (~449 in 2023), suggesting a niche indication or early revenue ramp with potential for team expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
EXKIVITY currently shows zero linked job postings, but the peak-lifecycle stage and Takeda sponsorship suggest active commercial teams are in place. Roles would typically span brand management, field sales, MSL, and market access functions to drive adoption and maintain market position.
Brand ManagerMedical Science Liaison
Worked on EXKIVITY at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.